Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies

Patients with acute myeloblastic leukemia or higher risk myelodysplastic syndromes with 5q deletion (generally within a complex karyotype) respond poorly to intensive chemotherapy and have very poor survival. In this population, we evaluated escalating doses of lenalidomide combined with intensive c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Ades, Lionel, Prebet, Thomas, Stamatoullas, Aspasia, Recher, Christian, Guieze, Romain, Raffoux, Emmanuel, Bouabdallah, Krimo, Hunault, Mathilde, Wattel, Eric, Stalnikiewicz, Laure, Toma, Andrea, Dombret, Hervé, Vey, Norbert, Sebert, Marie, Gardin, Claude, Chaffaut, Cendrine, Chevret, Sylvie, Fenaux, Pierre
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2017
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5395113/
https://ncbi.nlm.nih.gov/pubmed/28034993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.151894
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados